NO20014049L - Kontrollert frigjörings-formulering for behandling av COPD - Google Patents

Kontrollert frigjörings-formulering for behandling av COPD

Info

Publication number
NO20014049L
NO20014049L NO20014049A NO20014049A NO20014049L NO 20014049 L NO20014049 L NO 20014049L NO 20014049 A NO20014049 A NO 20014049A NO 20014049 A NO20014049 A NO 20014049A NO 20014049 L NO20014049 L NO 20014049L
Authority
NO
Norway
Prior art keywords
copd
treatment
controlled release
release formulation
formulation
Prior art date
Application number
NO20014049A
Other languages
English (en)
Other versions
NO20014049D0 (no
Inventor
Patrick G Faulkner
Jamie J Lucca
Thomas J Wrzosek
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20014049D0 publication Critical patent/NO20014049D0/no
Publication of NO20014049L publication Critical patent/NO20014049L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014049A 1999-02-23 2001-08-20 Kontrollert frigjörings-formulering for behandling av COPD NO20014049L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12129199P 1999-02-23 1999-02-23
PCT/US2000/004713 WO2000050011A1 (en) 1999-02-23 2000-02-22 Controlled release formulation for treating copd

Publications (2)

Publication Number Publication Date
NO20014049D0 NO20014049D0 (no) 2001-08-20
NO20014049L true NO20014049L (no) 2001-10-22

Family

ID=22395738

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014049A NO20014049L (no) 1999-02-23 2001-08-20 Kontrollert frigjörings-formulering for behandling av COPD

Country Status (29)

Country Link
US (1) US20030211152A1 (no)
EP (1) EP1154758A4 (no)
JP (1) JP2002537320A (no)
KR (1) KR20010112279A (no)
CN (1) CN1195496C (no)
AR (1) AR028986A1 (no)
AU (1) AU3501500A (no)
BG (1) BG105905A (no)
BR (1) BR0008382A (no)
CA (1) CA2366747A1 (no)
CO (1) CO5150233A1 (no)
CZ (1) CZ20013025A3 (no)
EA (1) EA200100906A1 (no)
HK (1) HK1043045A1 (no)
HU (1) HUP0200134A3 (no)
ID (1) ID29792A (no)
IL (1) IL144603A0 (no)
MA (1) MA25386A1 (no)
MY (1) MY121142A (no)
NO (1) NO20014049L (no)
NZ (1) NZ527716A (no)
OA (1) OA11836A (no)
PE (1) PE20001496A1 (no)
PL (1) PL350287A1 (no)
SK (1) SK12072001A3 (no)
TR (1) TR200102448T2 (no)
TW (1) TWI224013B (no)
WO (1) WO2000050011A1 (no)
ZA (1) ZA200106803B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203682A3 (en) * 1999-10-29 2003-10-28 Smithkline Beecham Plc Method for administering a phosphodiesterase 4 inhibitor
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
JP4510383B2 (ja) * 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
NZ532279A (en) * 2001-09-19 2006-02-24 Altana Pharma Ag Combination of a PDE inhibitor and a leukotriene receptor antagonist
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
WO2005030178A1 (en) * 2003-09-30 2005-04-07 Lupin Ltd. Extended release formulation of beta-lactam antibiotics
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
MX2007001706A (es) * 2004-08-13 2007-04-12 Boehringer Ingelheim Int Formulacion de comprimidos de liberacion extendida que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para su fabricacion y su uso.
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
PL3911304T3 (pl) * 2019-01-15 2023-12-04 UNION therapeutics A/S Preparat w postaci tabletek o zmodyfikowanym uwalnianiu, zawierający inhibitory fosfodiesterazy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297088A (no) * 1961-01-31
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
WO1993019749A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
IL144603A0 (en) 2002-05-23
HK1043045A1 (zh) 2002-09-06
EP1154758A4 (en) 2007-09-05
SK12072001A3 (sk) 2002-01-07
PL350287A1 (en) 2002-12-02
US20030211152A1 (en) 2003-11-13
CN1347314A (zh) 2002-05-01
NZ527716A (en) 2005-03-24
MA25386A1 (fr) 2002-04-01
HUP0200134A2 (hu) 2002-05-29
CO5150233A1 (es) 2002-04-29
WO2000050011A1 (en) 2000-08-31
EA200100906A1 (ru) 2002-02-28
OA11836A (en) 2005-08-22
BG105905A (bg) 2002-04-30
CN1195496C (zh) 2005-04-06
TR200102448T2 (tr) 2003-03-21
BR0008382A (pt) 2002-02-05
TWI224013B (en) 2004-11-21
KR20010112279A (ko) 2001-12-20
CZ20013025A3 (cs) 2002-07-17
ID29792A (id) 2001-10-11
NO20014049D0 (no) 2001-08-20
CA2366747A1 (en) 2000-08-31
AR028986A1 (es) 2003-06-04
JP2002537320A (ja) 2002-11-05
ZA200106803B (en) 2002-08-19
PE20001496A1 (es) 2001-02-08
HUP0200134A3 (en) 2003-03-28
MY121142A (en) 2005-12-30
AU3501500A (en) 2000-09-14
EP1154758A1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
AR027907A1 (es) Composicion de liberacion controlada
NO20021540L (no) Sammensetninger med kontrollert frigivelse omfattende nimesulfid
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
NO20014049L (no) Kontrollert frigjörings-formulering for behandling av COPD
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20015288D0 (no) Anvendelse av makrolide forbindelser for behandling av tört öye
IL149107A0 (en) Formulation of substituted benzimidazoles
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20014301L (no) Sammensetninger med kontrollert frigivelse av betahistin
NO20014222L (no) Fremgangsmåte for behandling av COPD
NO20020784L (no) Medikament for behandling av brudd
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO20013651D0 (no) Anvendelse av fosfororganiske forbindelser for profylaktisk og terapeutisk behandling av infeksjoner
NO20014383L (no) Fremgangsmåte for fremstilling av syklo-(Asp-DPhe-NMeVal-Arg- Gly)
NO20000805D0 (no) Fremgangsmåte for fremstilling av organiske azider
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol